Posted on November 6th, 2015 by Editor
By Charles H. Weaver, MD
The American Cancer Society (ACS) has recently changed its recommendations for breast cancer screening. The ACS now recommends:
The most significant, and potentially controversial, change in the ACS guidelines is the recommendation that women at average risk wait until they reach age 45 for their first breast cancer screening, as opposed to getting a baseline mammogram at age 40.
Other respected medical organizations, such as the American Congress of Obstetricians and Gynecologists, the National Comprehensive Cancer Network, and the American Medical Association continue to recommend annual screening beginning at age 40, while the U.S. Preventive Services Task Force (USPSTF) has recommended increasing the age to 50. In light of the ACS position, the National Consortium of Breast Centers has just reaffirmed that mammography screening should begin at the age of 40 for women of average risk.
Why would the ACS increase the age to 45 years for routine breast screening to begin? The organization’s stated concern is over diagnosis from early screening and the potential for increased morbidity and anxiety among women who will ultimately be found not to have invasive breast cancer.
Although not specifically stated, many suspect increased societal costs attributed to screening mammography have contributed to the ACS recommendations. This raises concerns as to whether the ACS is advocating for individual cancer patients or is more closely aligned with government and policy maker’s objectives. The major impact from the ACS recommendations are that they will influence insurance coverage decisions resulting in women under 45 having to pay for their mammograms instead of them being covered by their insurance.
Breast cancer remains the number one malignant cause of death in women between the ages of 35 and 60, and is a leading cause of death of women in their thirties, forties and fifties, overall. In fact a figure in the actual ACS analysis shows that women diagnosed before age 45 account for over 25 percent of person-years of life lost due to breast cancer.
In their analysis, the ACS authors note that women between ages 40 and 49 are more likely to have a false-positive mammogram than older women. While this is an important consideration, if the problem is that premenopausal women are so vulnerable to erroneous screening, perhaps the focus of reform should be on improved screening technology instead of reducing screening. Potential improvements could include same-day ultrasound and a requirement that all images be interpreted by breast imaging sub-specialists. Moreover, the establishment of a “baseline” mammogram at 40 might help reduce false positive mammograms in later years.
How the ACS concludes that 45 years is the threshold when the risk-benefit of screening mammograms suddenly tips to justify screening mammograms from never to every single year seems completely arbitrary. There’s every reason to begin breast cancer screening at age 40 years: both screening methods and pathology tools have improved, so there should be less for women to be anxious about than in previous years. Concern about fear or anxiety should not form the basis of any screening recommendations. The ACS should be encouraging women to take charge of their health and be empowered and engaged in the process.
The ACS recommendation to cease screening mammograms for older women who are unwell and unlikely to live for another decade does make sense, as does the third recommendation to cease clinical breast examination as a screening tool, which is consistent with the results of clinical trials that don’t support the utility of doctors or nurses examining patients’ breasts for cancerous lumps.
Ultimately, women should review the new guidelines with their physician. The ACS failed to acknowledge that most women at age 40 are at sufficient risk for developing breast cancer that it’s worth getting screened. They should be advised to do so, and not be afraid.
You must be logged-in to the site to post a comment.
© 1998-2015 CancerConnect · All Rights Reserved
The information contained above is general in nature and is not intended as a guide to self-medication by consumers or meant to substitute for advice provided by your own physician or other medical professional. The reader is advised to consult with a physician or other medical professional and to check product information (including packaging inserts) for changes and new information regarding dosage, precautions, and contra indication before administering any drug, herb, supplement, compound, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Page loaded in 0.281 seconds